KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Other financing activities (2017 - 2021)

Historic Other financing activities for Twist Bioscience (TWST) over the last 4 years, with Q4 2021 value amounting to -$2.6 million.

  • Twist Bioscience's Other financing activities fell 614.11% to -$2.6 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$11.0 million, marking a year-over-year decrease of 17335.32%. This contributed to the annual value of -$10.8 million for FY2021, which is 34812.06% down from last year.
  • Per Twist Bioscience's latest filing, its Other financing activities stood at -$2.6 million for Q4 2021, which was down 614.11% from -$2.6 million recorded in Q3 2021.
  • Twist Bioscience's 5-year Other financing activities high stood at $1.4 million for Q1 2018, and its period low was -$3.3 million during Q1 2021.
  • Its 4-year average for Other financing activities is -$1.1 million, with a median of -$611500.0 in 2020.
  • Examining YoY changes over the last 5 years, Twist Bioscience's Other financing activities showed a top increase of 614.11% in 2021 and a maximum decrease of 75666.67% in 2021.
  • Quarter analysis of 4 years shows Twist Bioscience's Other financing activities stood at $470000.0 in 2017, then decreased by 7.66% to $434000.0 in 2018, then plummeted by 655.3% to -$2.4 million in 2020, then decreased by 6.14% to -$2.6 million in 2021.
  • Its Other financing activities was -$2.6 million in Q4 2021, compared to -$2.6 million in Q3 2021 and -$2.5 million in Q2 2021.